Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas

Abstract

Mycosis fungoides (MF) represent the most common type of primary cutaneous lymphomas. Total skin electron beam (TSEB) therapy to a total skin administered dose of 36 Gy represents a very effective treatment regimen and its role in the management of MF is well established. Unfortunately, the issue in MF is that despite the proved effectiveness of radiation therapy, disease regress, and the main goal of TSEB treatment seems to be the prolongation of the overall response duration time. Taking into consideration the high radio‐sensitivity of the disease, lower radiation doses have been tested with acceptable and comparable results. We prospectively analyzed low dose TSEB in 14 patients treated at ATTIKON University Hospital from 2011 to 2017. After a median duration of follow up time of 39 months we found that low dose TSEB is an effective treatment option, since therapeutic results are more than acceptable, with minimal toxicity. The fact that it can be repeated safely in the natural course of a “regressive” disease makes it more attractive than the standard full dose scheme of 36 Gy.

Short‐term efficacy and safety of total skin electron beam therapy in mycosis fungoides: Systematic review and meta‐analysis

“…The study by Goujon et al 14 did fulfill the MF/SS standardized staging system and evaluation of outcomes despite being published before the official publication of the consensus paper, 3 and therefore we included it in the analysis. The characteristics of the studies included in the final analysis are summarized in Table 1 alongside patients demographic details 15–26 …”

“…The characteristics of the studies included in the final analysis are summarized in Table 1 alongside patients demographic details. [15][16][17][18][19][20][21][22][23][24][25][26] These studies included 616 patients, of which 67% were males.…”

“…The characteristics of the studies included in the final analysis are summarized in Table 1 alongside patients demographic details. 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 …”